Please Wait.....
Report
Intravenous (IV) Hydration Therapy Market By Service (Immune boosters, Energy boosters, Skin care, Migraine, Others), By Component (Medicated, Non-medicated) By End user (Hospital & clinics, Wellness centers & spas, Home healthcare, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 220 Pages I Allied Market Research
Intravenous (IV) Hydration Therapy Market
The intravenous (IV) hydration therapy market was valued at $2.3 billion in 2023 and is projected to reach $4.9 billion by 2033, growing at a CAGR of 7.8% from 2024 to 2033.
Intravenous (IV) hydration therapy is the medical procedure in which medications,fluids, vitamins, and electrolytes are infused directly into the bloodstream through a vein. The therapy is a highly effective procedure as it ensures efficient and quick replenishment of essential fluids and nutrients lost due to dehydration. Dehydration is the excessive loss of fluids from the body caused by some illness, excessive alcohol consumption, or intense physical activity. The treatment is applicable in diverse medical settings for the management of chronic conditions, preoperative & postoperative care, and to cure patients with severe infections or gastrointestinal problems.
One of the key drivers of the intravenous (IV) hydration therapy market is increase in uptight lifestyle among individuals with high stress levels. A stressed lifestyle is one of the most common reasons for rising dehydration among individuals. In addition, the geriatric population is growing exponentially across the globe, who are highly susceptible to ailments and hospitalization. This boosts the demand for IV hydration therapy, thus augmenting the market growth. In recent times, the administration of IV therapy as a part of self-care routine or rejuvenation is trending, particularly among celebrities. Moreover, specialized centers called "hydration bars" are being established for people to receive therapy as a form of relaxation.
However, the availability of other alternatives for hydration therapy, such as the oral rehydration solutions restrain the development of the market. Furthermore, the shortage of dedicated medical facilities and well-trained staff, particularly in rural areas, presents challenges for the expansion of the market. On the contrary, advancements in technology and modifications in the conventional formulations administered during treatment are presenting lucrative opportunities for market growth. For instance, personalized solutions are being developed according to the requirements of every individual, hence aiding them to achieve their health goal.
Segment Review
The intravenous (IV) hydration therapy market is segmented into service, component, end user, and region. On the basis of service, the market is divided into immune boosters, energy boosters, skin care, migraine, and others. By component, it is bifurcated into medicated and non-medicated. As per end user, it is categorizedinto hospital & clinics, wellness centers & spas, home healthcare, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of service, the immune boosters segment dominates the market.
By component, the medicated segmented experiences significant demand in the market.
As per end user, the hospital & clinics segment acquires a high share of the market.
Region wise, North America leads the market.
Competition Analysis
The major players operating in theglobal intravenous (IV) hydration therapy market include Davita, Nikkiso Co. Ltd., Core IV Therapy, LLC, Cryojuvenate UK Ltd., B. Braun Medical Inc., Otsuka Pharmaceutical Co., Ltd., NexGen Health, JW Life Science Corporation, Amanta Healthcare Limited., and Baxter International Inc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
- Reimbursement Scenario
Key Market Segments
By Service
- Immune boosters
- Energy boosters
- Skin care
- Migraine
- Others
By Component
- Medicated
- Non-medicated
By End User
- Hospital clinics
- Wellness centers spas
- Home healthcare
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Davita
- Nikkiso Co. Ltd.
- Core IV Therapy, LLC
- Cryojuvenate UK Ltd.
- B. Braun Medical Inc.
- Otsuka Pharmaceutical Co., Ltd.
- NexGen Health
- JW Life Science Corporation
- Amanta Healthcare Limited.
- Baxter International Inc.?
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ZERO EMISSION BUILDING MARKET, BY ELEMENT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Element Type
4.2. Lighting
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Walls Roofs
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Heating, Ventilation, And Air Conditioning (HVAC) Systems
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Others
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: ZERO EMISSION BUILDING MARKET, BY BUILDING TYPE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Building Type
5.2. Residential
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Commercial
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: ZERO EMISSION BUILDING MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Element Type
6.2.3. Market Size and Forecast, By Building Type
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Zero Emission Building Market
6.2.5.1. Market Size and Forecast, By Element Type
6.2.5.2. Market Size and Forecast, By Building Type
6.2.6. Canada Zero Emission Building Market
6.2.6.1. Market Size and Forecast, By Element Type
6.2.6.2. Market Size and Forecast, By Building Type
6.2.7. Mexico Zero Emission Building Market
6.2.7.1. Market Size and Forecast, By Element Type
6.2.7.2. Market Size and Forecast, By Building Type
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Element Type
6.3.3. Market Size and Forecast, By Building Type
6.3.4. Market Size and Forecast, By Country
6.3.5. France Zero Emission Building Market
6.3.5.1. Market Size and Forecast, By Element Type
6.3.5.2. Market Size and Forecast, By Building Type
6.3.6. Germany Zero Emission Building Market
6.3.6.1. Market Size and Forecast, By Element Type
6.3.6.2. Market Size and Forecast, By Building Type
6.3.7. Italy Zero Emission Building Market
6.3.7.1. Market Size and Forecast, By Element Type
6.3.7.2. Market Size and Forecast, By Building Type
6.3.8. Spain Zero Emission Building Market
6.3.8.1. Market Size and Forecast, By Element Type
6.3.8.2. Market Size and Forecast, By Building Type
6.3.9. UK Zero Emission Building Market
6.3.9.1. Market Size and Forecast, By Element Type
6.3.9.2. Market Size and Forecast, By Building Type
6.3.10. Russia Zero Emission Building Market
6.3.10.1. Market Size and Forecast, By Element Type
6.3.10.2. Market Size and Forecast, By Building Type
6.3.11. Rest of Europe Zero Emission Building Market
6.3.11.1. Market Size and Forecast, By Element Type
6.3.11.2. Market Size and Forecast, By Building Type
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Element Type
6.4.3. Market Size and Forecast, By Building Type
6.4.4. Market Size and Forecast, By Country
6.4.5. China Zero Emission Building Market
6.4.5.1. Market Size and Forecast, By Element Type
6.4.5.2. Market Size and Forecast, By Building Type
6.4.6. Japan Zero Emission Building Market
6.4.6.1. Market Size and Forecast, By Element Type
6.4.6.2. Market Size and Forecast, By Building Type
6.4.7. India Zero Emission Building Market
6.4.7.1. Market Size and Forecast, By Element Type
6.4.7.2. Market Size and Forecast, By Building Type
6.4.8. South Korea Zero Emission Building Market
6.4.8.1. Market Size and Forecast, By Element Type
6.4.8.2. Market Size and Forecast, By Building Type
6.4.9. Australia Zero Emission Building Market
6.4.9.1. Market Size and Forecast, By Element Type
6.4.9.2. Market Size and Forecast, By Building Type
6.4.10. Thailand Zero Emission Building Market
6.4.10.1. Market Size and Forecast, By Element Type
6.4.10.2. Market Size and Forecast, By Building Type
6.4.11. Malaysia Zero Emission Building Market
6.4.11.1. Market Size and Forecast, By Element Type
6.4.11.2. Market Size and Forecast, By Building Type
6.4.12. Indonesia Zero Emission Building Market
6.4.12.1. Market Size and Forecast, By Element Type
6.4.12.2. Market Size and Forecast, By Building Type
6.4.13. Rest of Asia-Pacific Zero Emission Building Market
6.4.13.1. Market Size and Forecast, By Element Type
6.4.13.2. Market Size and Forecast, By Building Type
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Element Type
6.5.3. Market Size and Forecast, By Building Type
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Zero Emission Building Market
6.5.5.1. Market Size and Forecast, By Element Type
6.5.5.2. Market Size and Forecast, By Building Type
6.5.6. South Africa Zero Emission Building Market
6.5.6.1. Market Size and Forecast, By Element Type
6.5.6.2. Market Size and Forecast, By Building Type
6.5.7. Saudi Arabia Zero Emission Building Market
6.5.7.1. Market Size and Forecast, By Element Type
6.5.7.2. Market Size and Forecast, By Building Type
6.5.8. UAE Zero Emission Building Market
6.5.8.1. Market Size and Forecast, By Element Type
6.5.8.2. Market Size and Forecast, By Building Type
6.5.9. Argentina Zero Emission Building Market
6.5.9.1. Market Size and Forecast, By Element Type
6.5.9.2. Market Size and Forecast, By Building Type
6.5.10. Rest of LAMEA Zero Emission Building Market
6.5.10.1. Market Size and Forecast, By Element Type
6.5.10.2. Market Size and Forecast, By Building Type
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Skanska AB
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Bouygues Construction
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Turner Construction Company
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Siemens AG
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Johnson Controls International Plc
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Schneider Electric
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Tesla, Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. SunPower Corporation
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Mitsubishi Electric Corporation
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. GreenTree Global.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 2. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR IMMUNE BOOSTERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR ENERGY BOOSTERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR SKIN CARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MIGRAINE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 8. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MEDICATED, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR NON-MEDICATED, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 11. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOSPITAL CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR WELLNESS CENTERS SPAS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOME HEALTHCARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 18. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 20. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 21. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 22. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 23. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 24. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 25. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 28. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 31. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 32. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 34. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 35. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 37. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 38. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 39. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 40. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 41. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 43. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 44. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 45. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 46. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 47. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 49. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 50. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 53. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 54. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 56. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 57. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 58. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 59. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 60. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 61. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 62. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 63. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 64. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 65. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 66. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 67. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 68. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 69. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 71. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 72. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 75. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 76. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 78. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 79. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 80. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 81. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 82. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 83. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 84. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 85. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 87. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 88. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 89. DAVITA: KEY EXECUTIVES
TABLE 90. DAVITA: COMPANY SNAPSHOT
TABLE 91. DAVITA: OPERATING SEGMENTS
TABLE 92. DAVITA: PRODUCT PORTFOLIO
TABLE 93. DAVITA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. NIKKISO CO. LTD.: KEY EXECUTIVES
TABLE 95. NIKKISO CO. LTD.: COMPANY SNAPSHOT
TABLE 96. NIKKISO CO. LTD.: OPERATING SEGMENTS
TABLE 97. NIKKISO CO. LTD.: PRODUCT PORTFOLIO
TABLE 98. NIKKISO CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. CORE IV THERAPY, LLC: KEY EXECUTIVES
TABLE 100. CORE IV THERAPY, LLC: COMPANY SNAPSHOT
TABLE 101. CORE IV THERAPY, LLC: OPERATING SEGMENTS
TABLE 102. CORE IV THERAPY, LLC: PRODUCT PORTFOLIO
TABLE 103. CORE IV THERAPY, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. CRYOJUVENATE UK LTD.: KEY EXECUTIVES
TABLE 105. CRYOJUVENATE UK LTD.: COMPANY SNAPSHOT
TABLE 106. CRYOJUVENATE UK LTD.: OPERATING SEGMENTS
TABLE 107. CRYOJUVENATE UK LTD.: PRODUCT PORTFOLIO
TABLE 108. CRYOJUVENATE UK LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. B. BRAUN MEDICAL INC.: KEY EXECUTIVES
TABLE 110. B. BRAUN MEDICAL INC.: COMPANY SNAPSHOT
TABLE 111. B. BRAUN MEDICAL INC.: OPERATING SEGMENTS
TABLE 112. B. BRAUN MEDICAL INC.: PRODUCT PORTFOLIO
TABLE 113. B. BRAUN MEDICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 115. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 116. OTSUKA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 117. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 118. OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 119. NEXGEN HEALTH: KEY EXECUTIVES
TABLE 120. NEXGEN HEALTH: COMPANY SNAPSHOT
TABLE 121. NEXGEN HEALTH: OPERATING SEGMENTS
TABLE 122. NEXGEN HEALTH: PRODUCT PORTFOLIO
TABLE 123. NEXGEN HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 124. JW LIFE SCIENCE CORPORATION: KEY EXECUTIVES
TABLE 125. JW LIFE SCIENCE CORPORATION: COMPANY SNAPSHOT
TABLE 126. JW LIFE SCIENCE CORPORATION: OPERATING SEGMENTS
TABLE 127. JW LIFE SCIENCE CORPORATION: PRODUCT PORTFOLIO
TABLE 128. JW LIFE SCIENCE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129. AMANTA HEALTHCARE LIMITED.: KEY EXECUTIVES
TABLE 130. AMANTA HEALTHCARE LIMITED.: COMPANY SNAPSHOT
TABLE 131. AMANTA HEALTHCARE LIMITED.: OPERATING SEGMENTS
TABLE 132. AMANTA HEALTHCARE LIMITED.: PRODUCT PORTFOLIO
TABLE 133. AMANTA HEALTHCARE LIMITED.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 134. BAXTER INTERNATIONAL INC.?: KEY EXECUTIVES
TABLE 135. BAXTER INTERNATIONAL INC.?: COMPANY SNAPSHOT
TABLE 136. BAXTER INTERNATIONAL INC.?: OPERATING SEGMENTS
TABLE 137. BAXTER INTERNATIONAL INC.?: PRODUCT PORTFOLIO
TABLE 138. BAXTER INTERNATIONAL INC.?: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION
FIGURE 2. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 3. SEGMENTATION INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 4. TOP INVESTMENT POCKET IN INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALINTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 11. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY SERVICE
FIGURE 12. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR IMMUNE BOOSTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR ENERGY BOOSTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR SKIN CARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MIGRAINE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY COMPONENT
FIGURE 18. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MEDICATED, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR NON-MEDICATED, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY END USER
FIGURE 21. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOSPITAL CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR WELLNESS CENTERS SPAS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOME HEALTHCARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 29. COMPETITIVE DASHBOARD
FIGURE 30. COMPETITIVE HEATMAP: INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 31. TOP PLAYER POSITIONING, 2023
FIGURE 32. DAVITA: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. DAVITA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. DAVITA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. NIKKISO CO. LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. NIKKISO CO. LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. NIKKISO CO. LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. CORE IV THERAPY, LLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. CORE IV THERAPY, LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. CORE IV THERAPY, LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. CRYOJUVENATE UK LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. CRYOJUVENATE UK LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. CRYOJUVENATE UK LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. B. BRAUN MEDICAL INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. B. BRAUN MEDICAL INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. B. BRAUN MEDICAL INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. OTSUKA PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. OTSUKA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. OTSUKA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. NEXGEN HEALTH: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. NEXGEN HEALTH: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. NEXGEN HEALTH: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. JW LIFE SCIENCE CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 54. JW LIFE SCIENCE CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. JW LIFE SCIENCE CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 56. AMANTA HEALTHCARE LIMITED.: NET SALES, 2021-2023 ($BILLION)
FIGURE 57. AMANTA HEALTHCARE LIMITED.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 58. AMANTA HEALTHCARE LIMITED.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 59. BAXTER INTERNATIONAL INC.?: NET SALES, 2021-2023 ($BILLION)
FIGURE 60. BAXTER INTERNATIONAL INC.?: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 61. BAXTER INTERNATIONAL INC.?: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security